Abstract
The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 81-84 |
| Number of pages | 4 |
| Journal | Metabolic Syndrome and Related Disorders |
| Volume | 9 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 1 2011 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Cite this
The ACCORD study : The devil is in the details. / Siegel, David; Swislocki, Arthur L.
In: Metabolic Syndrome and Related Disorders, Vol. 9, No. 2, 01.04.2011, p. 81-84.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The ACCORD study
T2 - The devil is in the details
AU - Siegel, David
AU - Swislocki, Arthur L
PY - 2011/4/1
Y1 - 2011/4/1
N2 - The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.
AB - The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.
UR - http://www.scopus.com/inward/record.url?scp=79953100939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953100939&partnerID=8YFLogxK
U2 - 10.1089/met.2010.0119
DO - 10.1089/met.2010.0119
M3 - Article
C2 - 21166575
AN - SCOPUS:79953100939
VL - 9
SP - 81
EP - 84
JO - Metabolic Syndrome and Related Disorders
JF - Metabolic Syndrome and Related Disorders
SN - 1540-4196
IS - 2
ER -